Ann: Strategic Partnership for Clinical R&D in China worth $4M, page-7

This is a $12 million capped company. Its laughable how this stock can be trading at these multiples vs forward earnings (with a healthy execution risk probability) on this contract alone. The contracts and collaborations were always going to start to flow, especially with A*STAR, the leading R&D arm of the Singapore Govt. Agency.

August will see some nice earnings growth resumed after the EU medical device regulation changes and investors will be wondering how the hell this stock traded under 10c, let alone 20c come September IMO.

This is in part the usual massive EOFY tax sell off IMO, that we saw last year too (it was trading 10 cents by the end of June and 30 cents by the end of August 2022). I've heavily increased my position down here on the expectation of this sell off and further contracts/collaborations in the 2024 FY.